How this PhD works
The EPSRC Centre for Doctoral Training works in collaboration with our academic partners at UCL and a number of leading pharmaceutical industry partners. Together, our aim is to produce collaborative, fundamental, multidisciplinary and pharmaceutically-focused research using the most modern instrumentation and facilities.
In 2014, the School of Pharmacy, in partnership with University College London’s School of Pharmacy, EPSRC, and leading pharmaceutical industry companies (including Alliance Boots, AstraZeneca, GlaxoSmithKline, and Pfizer) established a new centre of excellence in Advanced Therapeutics and Nanomedicines - the science of developing formulation technologies that enable precise engineering of therapeutics down to the molecular level.
Intake and duration
The Centre trains 12 students a year, six based at Nottingham and six at UCL. PhD programmes are of four years duration, with the equivalent of one year Masters level training and three years doctoral level research.
Specific entry requirements
English language requirements - IELTS 6.0 (with no less than 5.5 in each element)
How the research is structured
initial training covers key areas of pharmaceutical science, beginning with an introductory module in Advanced Therapeutics, peer-peer learning workshops, industry immersion mini-projects and ‘teamwork boot camps’ – designed to foster learning and networking across the cohorts and other Centres for Doctoral Training (CDTs).
On completion of this initial training, specific PhD projects are undertaken. These are highly multidisciplinary, drawing on aspects of pharmaceutical nanotechnology, biopharmaceuticals and advanced physical, mathematical and life sciences. Each University also organises introductory sessions on 'School Research Facilities', 'Core Skills in Laboratory Techniques' and 'Safety and Risk Assessment.’
Placements at varying points during the PhD programme enable students to engage and gain valuable industry experience with our industry partners across the whole healthcare technologies ‘ecosystem,’ covering start-up companies and pharmaceutical service providers, to large global pharma.